Skip to main content

Table 1 Baseline characteristics of patients included in the study

From: Follow-up care after treatment for prostate cancer: evaluation of a supported self-management and remote surveillance programme

  All Programme group Comparator group
(n = 627) (n = 293) (n = 334)
Centre
 1 155 (25) 99 (34) 56 (17)
 2 202 (32) 100 (34) 102 (31)
 3 146 (23) 53 (18) 93 (28)
 4 124 (20) 41 (14) 83 (25)
Ethnicitya
 White 607 (97) 281 (97) 326 (99)
 Mixed 2 (0) 1 (0) 1 (0)
 Asian 4 (1) 3 (1) 1 (0)
 Black 4 (1) 4 (1) 0
 Other 4 (1) 2 (1) 2 (1)
 Missing 6 (1) 2 (1) 4 (1)
Qualificationsa
 No qualifications 166 (27) 70 (24) 96 (30)
 GCSE/O level 106 (17) 46 (16) 60 (18)
 Vocational 131 (21) 63 (22) 68 (21)
 A level 45 (7) 28 (10) 17 (5)
 Undergraduate 54 (9) 27 (9) 27 (8)
 Postgraduate 34 (6) 21 (7) 13 (4)
 Other 81 (13) 35 (12) 46 (14)
 Missing 10 (2) 3 (1) 7 (2)
Employment statusa
 Retired 479 (77) 224 (77) 255 (77)
 Employed full time 56 (9) 27 (9) 29 (9)
 Employed part time 34 (5) 18 (6) 16 (5)
 Employed on sick leave 5 (1) 1 (0) 4 (1)
 Self employed 33 (5) 16 (6) 17 (5)
 Disabled or long term sick 13 (2) 3 (1) 10 (3)
 Unemployed 3 (0) 2 (1) 1 (0)
 Missing 4 (1) 2 (1) 2 (1)
Marital statusa
 Married/civil partnership 507 (81) 233 (80) 274 (82)
 Widowed 36 (6) 19 (6) 17 (5)
 Living with partner 33 (5) 17 (6) 16 (5)
 Divorced/separated 31 (5) 15 (5) 16 (5)
 Single 19 (3) 9 (3) 10 (3)
 Missing 1 (0) 0 1 (0)
Living
 In own home 554 (88) 260 (89) 294 (88)
 In rented home 57 (9) 29 (10) 28 (8)
 Temporary accommodation 3 (1) 1 (0) 2 (1)
 Other 13 (2) 3 (1) 10 (3)
Caring responsibilities for children or adultsa
 Yes 75 (12) 41 (14) 34 (10)
 No 548 (88) 251 (86) 297 (90)
 Missing 4 (1) 1 (0) 3 (1)
Access to the internet at homea
 Yes 530 (85) 254 (87) 276 (83)
 No 96 (15) 39 (13) 57 (17)
 Missing 1 (0) 0 1 (0)
Index of Multiple Deprivation decilea
 1 25 (4) 13 (5) 12 (4)
 2 28 (5) 15 (5) 13 (4)
 3 51 (8) 21 (7) 30 (9)
 4 88 (14) 39 (14) 49 (15)
 5 89 (15) 36 (13) 53 (16)
 6 75 (12) 34 (12) 41 (13)
 7 64 (10) 34 (12) 30 (9)
 8 72 (12) 41 (14) 31 (9)
 9 70 (11) 29 (10) 41 (13)
 10 53 (9) 24 (8) 29 (9)
 Missing 12 (2) 7 (2) 5 (2)
Age of participant (in years)
 Mean (SD) 70 (7) 70 (7) 71 (7)
 Min to max 44 to 91 45 to 84 44 to 91
Time since diagnosis (in years)a
 Mean (SD) 2 (2) 2 (2) 2 (2)
 Min to max 0 to 14 0 to 14 0 to 14
n 623 292 331
Time from treatmenta
 0–1 years 314 (51) 160 (56) 154 (47)
 > 1–2 years 185 (30) 69 (24) 116 (35)
 > 2–3 years 114 (19) 56 (20) 58 (18)
 Missing 14 (2) 8 (3) 6 (2)
Number of comorbidities
 Mean (SD) 2 (1) 2 (1) 2 (1)
 Min to max 0 to 6 0 to 5 0 to 6
Treatmenta
 Radical prostatectomy 178 (29) 83 (29) 95 (29)
 External Beam Radiotherapy (EBRT) 54 (9) 23 (8) 31 (9)
 Hormone therapy (HT) 91 (15) 27 (9) 64 (19)
 Brachytherapy (BT) 4 (1) 2 (1) 2 (1)
 EBRT and HT 264 (43) 143 (50) 121 (37)
 BT and HT 14 (2) 9 (3) 5 (2)
 BT and EBRT 3 (1) 1 (0) 2 (1)
 BT and EBRT and HT 12 (2) 1 (0) 11 (3)
 Missing 7 (1) 4 (1) 3 (1)
T Stagea
 T1 64 (11) 32 (11) 32 (11)
 T2 255 (44) 119 (42) 136 (45)
 T3 237 (40) 118 (42) 119 (39)
 T4 24 (4) 12 (4) 12 (4)
 T stage unknown 4 (1) 1 (0) 3 (1)
 Missing 43 (7) 11 (4) 32 (10)
N Stagea
 N0 528 (91) 262 (91) 266 (92)
 N1 33 (6) 14 (5) 19 (7)
 N stage unknown 17 (3) 12 (4) 5 (2)
 Missing 49 (8) 5 (2) 44 (13)
M Stagea
 M0 551 (95) 273 (95) 278 (95)
 M1 19 (3) 7 (2) 12 (4)
 M stage unknown 12 (2) 8 (3) 4 (1)
 Missing 45 (7) 5 (2) 40 (12)
PSA at diagnosisa
 Less than 10 287 (48) 142 (49) 145 (46)
 10 to 20 163 (27) 83 (29) 80 (26)
 More than 20 154 (25) 65 (22) 89 (28)
 Missing 23 (4) 3 (1) 20 (6)
Risk stratification (3)
 Advanced (metastatic) 17 (3) 7 (2) 10 (3)
 Localised high risk 65 (10) 31 (11) 34 (10)
 Localised intermediate risk 183 (29) 96 (33) 87 (26)
 Localised low risk 36 (6) 15 (5) 21 (6)
 Localised risk unknown 8 (1) 3 (1) 5 (2)
 Locally advanced 245 (39) 123 (42) 122 (37)
 Insufficient data 73 (12) 18 (6) 55 (17)
  1. aPercentages for non-missing categories calculated amongst cases with valid responses